Abstract

Casirivimab/Imdevimab for Management of Mild to Moderate COVID 19: An Indian Experience

Author(s): Vishesh Agrawal

Background: The  antibody cocktail (Casirivimab and Imdevimab) has been approved  in India for the treatment of mild to moderate coronavirus disease in adolescents and adults in specified high-risk groups. There is a paucity of experience published about use in Indian patients with mild to moderate COVID -19.

Objectives: The primary objectives of the study were time to COVID-19 symptoms resolution  and proportion of patients with disease progression defined in terms of oxygen requirement. The effect of BMI on outcomes of treatment was also assessed. The chief secondary objectives were to evaluate the safety and all-cause mortality in patients treated

Methodology: In this retrospective study patients with mild to moderate COVID  were enrolled. They were  treated with the antibody cocktail 1.2 gm  intravenously either on the day of diagnosis or within 24 hours of testing positive. The parameters of assessment included  : time to symptom resolution, duration of hospitalization, need for oxygen, need for ventilator support   and outcomes of hospitalization were evaluated

Results: Sixty three patients  (mean age: 54.87 years ± 17.83   years) were enrolled in the study .. Patients most commonly presented with symptoms of fever (52.4%) and cough (66.7%). Symptoms resolution occurred earliest  for fever( 1.41 years ± 0.74 days)  followed by sore throat (1.59 days ± 0.80  days). BMI had  no impact on  symptom resolution hospitalization and O₂ support regardless of the presence or absence of comorbidities .

Conclusion: Casirivimab/imdevimab improves outcomes in Indian patients.The efficacy of casirivimab/imdevimab   remains unaffected regardless of the age of the patient, body weight of the patient and the presence of comorbid diseases.